Upcoming tradeshows
Connect with us live to take advantage of physician-driven education and learn about the latest research and innovation.
Upcoming tradeshows
Connect with us live to take advantage of physician-driven education and learn about the latest research and innovation.
October 1–4, 2023
San Diego Convention Center
San Diego, California
Booth #2235
#ASTRO23
Featured Products: SpaceOAR™ Hydrogel, SpaceOAR Vue™ Hydrogel
Booth Highlights and Activities:
October 4–6, 2023
Oregon Convention Center
Portland, Oregon
Booth #107
#PFDWeek23
Featured Products: Solyx™ Single-Incision Sling System, Upsylon™ Y-Mesh
Booth Highlights and Activities:
October 23–27, 2023
International Convention Center
Jerusalem, Israel
#WCET23
Featured Products: LithoVue™ Elite Single-Use Digital Flexible Ureteroscope, Lumenis Pulse™ 120H Holmium Laser System with MOSES™ 2.0 Technology, Rezūm™ Water Vapor Therapy
Booth Highlights and Activities: Hands-on demos of LithoVue™ Elite Single-Use Digital Flexible Ureteroscope, Lumenis Pulse™ 120H Holmium Laser System with MOSES™ 2.0 Technology, Rezūm™ Water Vapor Therapy
Reference:
Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.
CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.
For information purposes only. The content of the referenced articles/publications are under the sole responsibility of the authors/publishers and does not represent the opinion of BSC.
All images are the property of Boston Scientific.
All trademarks are the property of their respective owners.
SpaceOAR™ Hydrogel and SpaceOAR Vue™ Hydrogel
SpaceOAR and SpaceOAR Vue Hydrogels are intended to temporarily position the anterior rectal wall away from the prostate during radiotherapy for prostate cancer and in creating this space it is the intent of SpaceOAR and SpaceOAR Vue Hydrogels to reduce the radiation dose delivered to the anterior rectum.
SpaceOAR and SpaceOAR Vue Hydrogels contain polyethylene glycol (PEG). SpaceOAR Vue Hydrogel contains iodine.
Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions and potential adverse events.
As with any medical treatment, there are some risks involved with the use of SpaceOAR and SpaceOAR Vue Hydrogels. Potential complications associated with SpaceOAR and SpaceOAR Vue Hydrogels include, but are not limited to: pain associated with SpaceOAR and SpaceOAR Vue Hydrogels injection, pain or discomfort associated with SpaceOAR and SpaceOAR Vue Hydrogels, local inflammatory reactions, infection (including abscess), urinary retention, urgency, constipation (acute, chronic, or secondary to outlet perforation), rectal tenesmus/muscle spasm, mucosal damage, ulcers, fistula, perforation (including prostate, bladder, urethra, rectum), necrosis, allergic reaction (localized or more severe reaction, such as anaphylaxis), embolism (venous or arterial embolism is possible and may present outside of the pelvis, potentially impacting vital organs or extremities), syncope and bleeding. The occurrence of one or more of these complications may require treatment or surgical intervention. URO-989811-AB
All images are the property of Boston Scientific.
All trademarks are the property of their respective owners.
Advantage Fit™ Transvaginal Mid-Urethral Sling System
For FEMALE Mid-Urethral Slings: Caution: U.S. Federal law restricts this device to sale by or on the order of a physician trained in use of surgical mesh for repair of stress urinary incontinence.
Refer to package insert provided with this product for complete Indications for Use, Contraindications, Warnings, Precautions, Adverse Events, and Instructions prior to using these products.
The following adverse events have been reported due to suburethral sling placement, any of which may be ongoing, but are not limited to: As with all implants, local irritation at the wound site and/or a foreign body response may occur, Foreign body reaction may be acute or chronic, Pain (pelvic, vaginal, groin/thigh, suprapubic, dyspareunia) (acute or chronic), Dyspareunia, Tissue responses to the mesh implant could include: erosion into organs (urethra, bladder or other surrounding tissues); exposure/extrusion into the vagina, Mesh contact with urine via erosion/exposure/extrusion may result in stone formation, scarring/scar contracture, Necrosis, fistula formation (acute or chronic), inflammation (acute or chronic), Mesh contracture, Tissue contracture, Vaginal shortening or stenosis that may result in dyspareunia and/or sexual dysfunction, Pain with intercourse that may not resolve, Exposed mesh may cause pain or discomfort to the patient’s partner during intercourse, Sexual dysfunction, including the inability to have intercourse. Like all foreign bodies, the mesh may potentiate an existing infection. Allergic reaction has been reported. Known risks of surgical procedures for the treatment of incontinence include: pain, ongoing pain (pelvic, vaginal, groin/thigh, suprapubic, dyspareunia), Severe, chronic pain, Apareunia, Leg weakness, Infection, De novo detrusor instability, Complete failure of the procedure/failure to resolve a patient’s stress urinary incontinence, Voiding dysfunction (incontinence, temporary or permanent lower urinary tract obstruction, difficulty urinating, pain with urination, overactive bladder, and retention), Bruising, bleeding (vaginal, hematoma formation), Abscess, Vaginal discharge, Dehiscence of vaginal incision, Edema and erythema at the wound site, Perforation or laceration of vessels, nerves, bladder, urethra or bowel may occur during placement. The following additional adverse events have been reported for the Solyx SIS System: Dysuria, Hematuria. The occurrence of these events may require surgical intervention and possible removal of the entire mesh. In some instances, these events may persist as a permanent condition after surgical intervention or other treatment. Removal of mesh or correction of mesh-related complications may involve multiple surgeries. Complete removal of mesh may not be possible and additional surgeries may not always fully correct the complications.
Coaptite™ Urethral Bulking Injection
Indications for Use: The COAPTITE™ Injectable Implant is indicated for soft tissue augmentation in the treatment of stress urinary incontinence (SUI) due to intrinsic sphincteric deficiency (ISD) in adult females.
CONTRAINDICATIONS: The COAPTITE Injectable Implant is contraindicated for use in a patient: who has significant history of urinary tract infections without resolution; who has current or acute conditions of cystitis or urethritis; who has fragile urethral mucosal lining.
POTENTIAL ADVERSE EVENTS that may occur include: Urinary Tract Infection, Cystitis, Vulvovaginal Mycotic Infection, Urinary Retention, Urge Incontinence, Micturition Urgency, Pollakiuria, Hematuria, Nocturia, Urethritis non-infective, Hemorrhage Urinary Tract, dysuria, erosion, erythema, embolic phenomena, and vascular occlusion.
WARNINGS:
PRECAUTIONS:
Disclaimers: Please refer to package insert provided with these products for complete Indications for Use, Contraindications, Warnings, Precautions, Adverse Events, and Instructions prior to using these products. CAUTION: Federal Law (USA) restricts this device to sale by or on the order of a physician trained in diagnostic and therapeutic cystoscopy. All trademarks are the property of their perspective owners. WH-989707-AB MAY2023
LithoVue™ Elite Single-Use Digital Flexible Ureteroscope System with intrarenal pressure monitoring
Product shown for informational purposes only — not meant as a promotion or offer for sale ù product pending CE Mark, not available for sale in the European Economic Area (EEA).
Lumenis Pulse™ 120H Holmium Laser System with MOSES™ 2.0 Technology
References:
The use of MOSES™ Technology in Urology, enabled in the Lumenis Pulse 120H system, is contraindicated for patients who are unable to receive endoscopic treatments or are intolerant to prolonged anesthesia, as well as for resection or excision of large, vascularized organs. Holmium lasers are intended solely for use by physicians trained in the use of the Ho:YAG (2.1μm) wavelength. Incorrect treatment settings can cause serious tissue damage. The laser should be used only on tissues that are fully observable. See the system user manual for a complete list of contraindications and risks.
The MOSES 2.0 Technology is inclusive of all MOSES 1.0 settings and features.
Boston Scientific acquired the global surgical business of Lumenis Ltd. Some registered names of products manufactured and sold by Boston Scientific may contain the term “Lumenis.” Lumenis is a registered trademark of Lumenis Be.
Rezūm™ Water Vapor Therapy
References:
The Rezūm™ System is intended to relieve symptoms, obstructions, and reduce prostate tissue associated with BPH. It is indicated for men ≥ 50 years of age with a prostate volume 30cm3 ≤ 80cm3. The Rezūm System is also indicated for treatment of prostate with hyperplasia of the central zone and/or a median lobe.